Spike Glycoprotein, Coronavirus
"Spike Glycoprotein, Coronavirus" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class I viral fusion protein that forms the characteristic spikes, or peplomers, found on the viral surface that mediate virus attachment, fusion, and entry into the host cell. During virus maturation, it is cleaved into two subunits: S1, which binds to receptors in the host cell, and S2, which mediates membrane fusion.
| Descriptor ID |
D064370
|
| MeSH Number(s) |
D12.776.543.512.500.665 D12.776.964.970.880.910.665
|
| Concept/Terms |
Spike Glycoprotein, Coronavirus- Spike Glycoprotein, Coronavirus
- Coronavirus Spike Glycoprotein
- Spike Protein, Coronavirus
- Coronavirus Spike Protein
- Glycoprotein S, Coronavirus
- Spike Glycoproteins, Coronavirus
|
Below are MeSH descriptors whose meaning is more general than "Spike Glycoprotein, Coronavirus".
Below are MeSH descriptors whose meaning is more specific than "Spike Glycoprotein, Coronavirus".
This graph shows the total number of publications written about "Spike Glycoprotein, Coronavirus" by people in this website by year, and whether "Spike Glycoprotein, Coronavirus" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 6 | 10 |
| 2022 | 3 | 10 | 13 |
| 2023 | 1 | 1 | 2 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Spike Glycoprotein, Coronavirus" by people in Profiles.
-
Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern. Sci Rep. 2025 Feb 14; 15(1):5549.
-
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025 Dec; 21(1):2450120.
-
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories. Viruses. 2024 12 18; 16(12).
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
-
Immunogenicity and safety of SARS-CoV-2 recombinant spike protein vaccine in South African people living with and without HIV-1 infection: A phase 2 randomised trial. J Infect. 2024 Dec; 89(6):106285.
-
T-cell responses to ancestral SARS-CoV-2 and Omicron variant among unvaccinated pregnant and postpartum women living with and without HIV in South Africa. Sci Rep. 2024 09 02; 14(1):20348.
-
Rapid intra-host diversification and evolution of SARS-CoV-2 in advanced HIV infection. Nat Commun. 2024 Aug 22; 15(1):7240.
-
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
-
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).